Poor clinical outcomes and immunoevasive contexture in CD161 + CD8 + T cells barren human pancreatic cancer.
Qiangda ChenHanlin YinZhenlai JiangTaochen HeYuqi XieWeilin MaoJiande HanSiyao LiuWenhui LouWenchuan WuJoseph R HabibJun YuLiang LiuNing PuPublished in: Journal for immunotherapy of cancer (2024)
T cell is a valuable and promising predictor for survival and therapeutic response to adjuvant chemotherapy in PDAC. Further research is warranted to validate its role in the risk stratification and optimization of therapeutic strategies.